WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2023)
Top diagnostic & research stocks in 2023 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
ENZ
ENZO BIOCHEM INC
$63.11MN/A0.00%N/AN/AN/AN/A
FONR
FONAR CORP
$130.04MN/A0.00%N/AN/AN/AN/A
QGEN
QIAGEN NV
$9.39BN/A0.00%N/AN/AN/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$10.11BN/A0.00%N/AN/AN/AN/A
IDXX
IDEXX LABORATORIES INC
$38.69BN/A0.00%N/AN/AN/AN/A
RVTY
REVVITY INC
$10.97B0.31%4.80%$0.0700$0.283%02024-01-182024-02-09
STRR
STAR EQUITY HOLDINGS INC
$17.57MN/A0.00%$0.5500N/AN/A0
MEDP
MEDPACE HOLDINGS INC
$8.31BN/A0.00%N/AN/AN/AN/A
ICLR
ICON PLC
$21.95BN/A0.00%N/AN/AN/AN/A
A
AGILENT TECHNOLOGIES INC
$37.39B0.70%23.10%$0.2250$0.9010%12023-12-292024-01-24
EXAS
EXACT SCIENCES CORP
$11.57BN/A0.00%N/AN/AN/AN/A
DGX
QUEST DIAGNOSTICS INC
$15.43B2.03%41.00%$0.7100$2.7937%02024-01-162024-01-31
CSTL
CASTLE BIOSCIENCES INC
$537.94MN/A0.00%N/AN/AN/AN/A
TWST
TWIST BIOSCIENCE CORP
$1.39BN/A0.00%N/AN/AN/AN/A
LH
LABORATORY CORP OF AMERICA HOLDINGS
$18.42B1.33%37.80%$0.7200$2.8823%02023-12-12
OLK
OLINK HOLDING AB (PUBL)
$3.21BN/A0.00%N/AN/AN/AN/A
DHR
DANAHER CORP
$165.01B0.47%13.20%$0.2700$1.066%1
TMO
THERMO FISHER SCIENTIFIC INC
$191.55B0.27%8.80%$0.3500$1.353%02023-12-142024-01-16
DMTK
DERMTECH INC
$55.13MN/A0.00%N/AN/AN/AN/A
DRIO
DARIOHEALTH CORP
$32.93MN/A0.00%N/AN/AN/AN/A
CDNA
CAREDX INC
$525.30MN/A0.00%N/AN/AN/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$23.68BN/A0.00%N/AN/AN/AN/A
WAT
WATERS CORP
$16.59BN/A0.00%N/AN/AN/AN/A
APDN
APPLIED DNA SCIENCES INC
$12.02MN/A0.00%N/AN/AN/AN/A
SERA
SERA PROGNOSTICS INC
$60.79MN/A0.00%N/AN/AN/AN/A
BNR
BURNING ROCK BIOTECH LTD
$84.93MN/A0.00%N/AN/AN/AN/A
RDNT
RADNET INC
$2.26BN/A0.00%N/AN/AN/AN/A
FLGT
FULGENT GENETICS INC
$817.28MN/A0.00%N/AN/AN/AN/A
GH
GUARDANT HEALTH INC
$2.97BN/A0.00%N/AN/AN/AN/A
NTRA
NATERA INC
$6.72BN/A0.00%N/AN/AN/AN/A
LAB
STANDARD BIOTOOLS INC
$204.84MN/A0.00%N/AN/AN/AN/A
NEOG
NEOGEN CORP
$3.67BN/A0.00%N/AN/AN/AN/A
BGLC
BIONEXUS GENE LAB CORP
$16.78MN/A0.00%N/AN/AN/AN/A
NOTV
INOTIV INC
$63.68MN/A0.00%N/AN/AN/AN/A
NEO
NEOGENOMICS INC
$2.32BN/A0.00%N/AN/AN/AN/A
ACRS
ACLARIS THERAPEUTICS INC
$61.98MN/A0.00%N/AN/AN/AN/A
PRPO
PRECIPIO INC
$9.69MN/A0.00%N/AN/AN/AN/A
XWEL
XWELL INC
$9.95MN/A0.00%N/AN/AN/AN/A
PRPH
PROPHASE LABS INC
$91.49MN/A0.00%$0.3000N/AN/A0
GTH
GENETRON HOLDINGS LTD
$112.71MN/A0.00%N/AN/AN/AN/A
PSNL
PERSONALIS INC
$75.02MN/A0.00%N/AN/AN/AN/A
AWH
ASPIRA WOMEN's HEALTH INC
$32.87MN/A0.00%N/AN/AN/AN/A
ME
23ANDME HOLDING CO
$412.51MN/A0.00%N/AN/AN/AN/A
STIM
NEURONETICS INC
$52.66MN/A0.00%N/AN/AN/AN/A
CHEK
CHECK-CAP LTD
$17.02MN/A0.00%N/AN/AN/AN/A
GENE
GENETIC TECHNOLOGIES LTD
$16.85MN/A0.00%N/AN/AN/AN/A
NVTA
INVITAE CORP
$145.54MN/A0.00%N/AN/AN/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$15.77MN/A0.00%N/AN/AN/AN/A
OPK
OPKO HEALTH INC
$1.13BN/A0.00%N/AN/AN/AN/A
NDRA
ENDRA LIFE SCIENCES INC
$8.39MN/A0.00%N/AN/AN/AN/A
ILMN
ILLUMINA INC
$16.19BN/A0.00%N/AN/AN/AN/A
ISPC
ISPECIMEN INC
$5.08MN/A0.00%N/AN/AN/AN/A
IQV
IQVIA HOLDINGS INC
$39.07BN/A0.00%N/AN/AN/AN/A
MYGN
MYRIAD GENETICS INC
$1.57BN/A0.00%N/AN/AN/AN/A
XGN
EXAGEN INC
$31.36MN/A0.00%N/AN/AN/AN/A
SHC
SOTERA HEALTH CO
$3.86BN/A0.00%N/AN/AN/AN/A
PMD
PSYCHEMEDICS CORP
$14.85M5.47%-30.90%$0.0700$0.1479%1
PRE
PRENETICS GLOBAL LTD
$49.32MN/A0.00%N/AN/AN/AN/A
BDSX
BIODESIX INC
$134.81MN/A0.00%N/AN/AN/AN/A
OCX
ONCOCYTE CORP
$31.39MN/A0.00%N/AN/AN/AN/A
LMDX
LUMIRADX LTD
$54.85MN/A0.00%N/AN/AN/AN/A
VNRX
VOLITIONRX LTD
$59.64MN/A0.00%N/AN/AN/AN/A
CNTG
CENTOGENE NV
$35.10MN/A0.00%N/AN/AN/AN/A
MDXH
MDXHEALTH SA
$8.73MN/AN/AN/AN/AN/AN/A
TTOO
T2 BIOSYSTEMS INC
$14.34MN/A0.00%N/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$18.18MN/AN/A$0.2200N/AN/A0
MYNZ
MAINZ BIOMED NV
$17.82MN/AN/AN/AN/AN/AN/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Dec 2023?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the top diagnostic & research stock with a Zen Score of 51, which is 24 points higher than the diagnostic & research industry average of 27. It passed 16 out of 33 due diligence checks and has strong fundamentals. Enzo Biochem has seen its stock lose -37.19% over the past year, underperforming other diagnostic & research stocks by -20 percentage points.

2. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) is the second best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Qiagen Nv has seen its stock lose -16.92% over the past year.

Qiagen Nv has an average 1 year price target of $50.50, an upside of 22.69% from Qiagen Nv's current stock price of $41.16.

Qiagen Nv stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Qiagen Nv, 50% have issued a Strong Buy rating, 25% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 1.12% over the past year, overperforming other diagnostic & research stocks by 18 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.03%, which is 1 percentage points higher than the diagnostic & research industry average of 1.51%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 41% indicates that its dividend yield is sustainable for the long-term.

2. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.33%, which is the same as the diagnostic & research industry average of 1.51%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 37.8% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) has an annual dividend yield of 0.7%, which is -1 percentage points lower than the diagnostic & research industry average of 1.51%. Agilent Technologies's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 23.1% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.12% in the last day, and down -0.14% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -37.19% in the past year. It has underperformed other stocks in the diagnostic & research industry by -20 percentage points.

2. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 14.43% in the past year. It has overperformed other stocks in the diagnostic & research industry by 31 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 1.12% in the past year. It has overperformed other stocks in the diagnostic & research industry by 18 percentage points.

Are diagnostic & research stocks a good buy now?

54.9% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 16.24% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 30.73x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.